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OBJECTIVE: To determine the outcome of recurrent Graves’ disease with ophthalmopathy (GO) following
bilateral total thyroidectomy (TT) in patients with no history of anti-inflammatory treatment with
steroids or radioactive iodine treatment.
METHODS: From May 2002 to August 2005, 35 patients (27 female, 8 male) with different stages 
of Graves’ disease underwent TT. The degree of ophthalmopathy was assessed by the NOSPECS scoring
system and thyrotropin receptor antibody (TRAb) levels were measured for the detection of thyroidal and
retro-orbital inflammatory activity before and after surgery.
RESULTS: The mean duration of thyroid disease was 21.4 months and mean follow-up was 422 days.
Significant improvement, which was defined as complete regression of periorbital oedema accompanied
by a > 1 point decrease in NOSPECS, was observed in 30 (85%) patients. The remaining five patients had
stable eye disease. The mean TRAb value and NOSPECS score before and after TT were 33.8 U/L versus
3.4 U/L and 3.0 versus 1.52, respectively, and the differences were statistically significant (p < 0.0000).
A major reduction in TRAb values achieved after TT was clearly indicative of undetectable inflammatory
activity and all the patients demonstrated negative TRAb values within 6 months of the operation. TT
was accomplished with very low morbidity (3%) and provided a significant reduction in TRAb levels with
attendant improvement in GO in the vast majority of patients in this study.
CONCLUSION: TT resulted in a significant reduction in TRAb levels with concomitant regression of
recurrent GO in all patients. The operative morbidity was very low and mortality was nil. However, the
long-term consequences of permanent hypothyroidism, which is the ultimate result of TT, are of major
concern. [Asian J Surg 2008;31(3):115–8]
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Introduction
With rapidly progressing eye changes, the type and tim-
ing of surgery is still a matter of debate in Graves’ disease,
and the surgical gold standard for the remission of eye
disease remains undetermined. Also, the impact of total
thyroidectomy (TT) is questionable in terms of providing
further regression of proptosis after its spontaneous
remission. It is claimed in some histological and serological
studies that the thyroid follicles and preorbital adipose
tissue fibroblasts have a common antigenic structure.1–4
Thus, total removal of antigen, which is essentially com-
prised of a B-cell population in the basement membrane
of thyroid follicles, would presumably stop the progres-
sion of ophthalmopathy with an abrupt remission of the
disease. In view of the mechanisms mentioned above, we
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conducted a prospective study to evaluate the impact of
TT on the clinical severity of recurrent Graves’ disease
with ophthalmopathy (GO), and to elucidate the factors
related to remission and recurrence of the disease in the
immediate and long-term follow-up.
Patients and methods
From May 2002 to August 2005, the data of 35 patients
(27 female, 8 male) presenting with different stages of
recurrent GO were collected before, at 6 months and
annually following TT. Recurrent disease was defined as
the onset of hyperthyroidism within 6 months of with-
drawal of antithyroid medication. Antithyroid drugs were
administered for at least 6 months and loading dosages
were not tapered within 6–8 weeks after starting therapy,
as per protocol. The ages of the patients ranged from 16
to 72 years, with a mean of 37 years. None of the patients
received anti-inflammatory treatment with oral steroids
or were pretreated with I131 before surgery. All patients
had preoperative ultrasonographic examination of the
thyroid to exclude nodular hyperplasia and had measure-
ment of radioiodine uptake for diagnosis of diffuse toxic
hyperplasia.
The unique treatment modality to achieve a euthyroid
state was administration of propylthiouracil (PTU) or
methimazol (MM) in this series. Thirty-two patients received
PTU and three cases were treated with MM, with the aver-
age loading and maintenance doses being 360 mg/day
and 22.3 mg/day for PTU and 289 mg/day and 10 mg/day
for MM. Seven patients required a beta-blocking agent,
propranolol, at a dose of 2–40 mg/day for hyperthyroidism-
induced tachycardia. A 25–40% reduction in resting pulse
rate was intended with this treatment. The mean duration
of antithyroid drug treatment was 15 months (range,
6–48 months).
The mean duration of thyroid disease, which was taken
as the time between first diagnosis of GO and surgery, was
21.4 months. The choice of operation was bilateral TT for
all patients with some degree of ophthalmopathy. Quan-
tification of ophthalmopathy depended on a modified
NOSPECS scoring as proposed by Wiersinga et al5 (Table).
The severity of GO was estimated by the sum of scores
obtained in each patient and qualified as mild, moderate
or severe according to the scores 1–2, 3–8 and 9–14, respec-
tively. The ophthalmological parameters were assessed by
the same clinician using a Hertel exophthalmometer.
None of the patients had ultrasonography or computed
tomography scan for the determination of the severity of
eye disease. To find any existing mediating activity of thyroid
stimulating hormone (TSH) receptor antibodies (TRAb)
on the clinical severity of GO, TRAb levels were detected
before the operation, during discharge and in the 6th
month of follow-up. A conventional luminescence receptor
bioassay (Brahms, TRAK Human D-16761 Hennigsdorf)
was used for the quantitative determination of TRAb with
the reference ranges of < 1 U/L, 1.0–1.5 U/L and > 1.5 U/L
being considered negative, equivocal and positive anti-
body titres, respectively. The same procedure was applied
to thyroid hormones, and serum samples were collected
for the measurement of TSH, free thyroxine (fT4) and free
triiodothyronine (fT3) by immunologic assay Immulite
2000 third generation for TSH, Immulite 200 for fT3,
Immulite 200 for fT4 (DPC Los Angeles, CA 90045-6900
USA) with reference values for TSH of 0.4–4.0 mIU/mL,
fT4 of 0.8–1.9 ng/mL and fT3 of 1.57–4.71 pg/mL.
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Table. Modified NOSPECS score for the classification of the severity of Graves’ ophthalmopathy
NOSPECS score
0 1 2 3
Lid retraction No Yes
Soft tissue inflammation* 0 1–4 5–8 > 8
Proptosis (mm) < 17 17–8 19–22 > 22
Site difference (mm) < 1 1–2 3–4 > 4
Extraocular muscle involvement No > 20° upgaze ≤ 20° upgaze
> 35° abduction ≤ 35° abduction
Corneal defects No Yes
*Upper lid oedema 0–2, lower lid oedema 0–2, conjunctival injection 1, conjunctival chemosis 1.
The standard surgical approach was that of capsular
dissection high on the lateral surface of the thyroid gland,
without dissection of the recurrent laryngeal nerve (RLN)
from the tracheoesophageal groove up to the cricopha-
ryngeal membrane, but with isthmectomy and pyramidal
lobectomy in all patients. The RLN was encountered in
every patient with this approach. The penetrating branches
of the inferior thyroid artery were divided and ligated
high on the surface of the gland. The vascular supply of
the RLN was preserved by minimizing dissection and
exposure of the nerve.
Follow-up ranged from 21 days to 1,309 days, with a
mean of 422 days in this study. The difference between
pre- and postoperative hormone and antibody values was
investigated by means of the Wilcoxon signed rank test.
The association between TRAb titres and NOSPECS scores
was evaluated by Spearman’s rank correlation analysis.
The level of significance was accepted as p < 0.05.
Results
Permanent hypoparathyroidism and nerve injury was
observed in only one of the 35 patients because of mini-
mal dissection around the parathyroid glands and RLN.
This was the first patient involved in this study group and
TT was performed after the isolation of the RLN and
parathyroid glands, which was a rather unsafe technique
when compared to our standard capsular dissection.
Significant improvement in ophthalmopathy, which
was qualified as completely regressed periorbital oedema
with a ≥ 1 point decrease in NOSPECS score, was observed
in 30 (85%) patients. The remaining five patients had no
signs of worsening and had stable eye disease. Preoperative
NOSPECS scores ranged from 1 to 7 with a mean of 2.84,
indicating moderately active eye disease. This was success-
fully reduced to a mean of 1.52 after the operation. The
difference in NOSPECS scores was significant between
the two periods (p < 0.0000).
Preoperative TRAb values ranged from 0.71 U/L to
19.3 U/L, with a mean of 4.84 U/L. Five patients had neg-
ative or equivocal TRAb values ranging between 1.10 U/L
and 1.34 U/L. However, the evaluation of TRAb speci-
mens collected during the first 6 months after the opera-
tion revealed a significant reduction of antibody levels in
almost all patients, with values ranging between 0.01 U/L
and 3.57 U/L, with a mean of 0.61 U/L. These results were
clearly indicative of undetectable inflammatory activity
and the difference between pre- and postoperative TRAb
values was significantly different (p < 0.0000).
There was no apparent and direct correlation between
preoperative TRAb levels and NOSPECS scores. Thus, the
rank of elevation in TRAb levels did not necessarily trans-
late into severity of ophthalmopathy in patients who
already had high initial antibody levels (p = 0.374; r =
0.178). However, there was a significant difference between
pre- and postoperative NOSPECS scores, indicating the
efficacy of TT in improving GO (p = 0.000; r = 0.75).
Hypothyroidism occurred in all patients after TT. The
mean pre- and postoperative serum TSH levels were
0.36 mIU/mL and 9.16 mIU/mL, respectively, and the dif-
ference between the means was statistically significant
(p = 0.000). These patients received thyroid hormone
replacement to keep TSH levels between 0.5 mIU/mL and
2.0 mIU/mL following the operation, and all achieved a
euthyroid state with a mean maintenance thyroxine dose
of 0.138 mg/day. The incidence of thyroid cancer was nil
in our series.
Discussion
Strong evidence exists for autoimmune pathophysiology
in Graves’ disease. In his study in 1967, Heimann demon-
strated lymphocyte infiltration with B-cell predominance
in the basement membrane of thyroid follicles in patients
with thyrotoxicosis.1 The importance of this ultrastruc-
ture was further supported by the detection of higher lev-
els of thyroid-stimulating antibody activity in thyroid
vein blood samples but not in peripheral vein samples of
patients with GO undergoing thyroid surgery. It was pos-
tulated in this study that the B cells infiltrating the thy-
roid follicles were the major source of these antibodies.2
Common autoantibodies between the thyroid gland and
the retro-orbital tissue have been demonstrated in patients
with GO.3 Moreover, the identification of thyrotropin
receptor and mRNA expression in fibroblasts located in
retro-orbital adipose tissue of patients with Graves’ disease
supported the autoimmune nature and common antigenic
structure of thyroid and retro-orbital adipocyte fibro-
blasts in this disease.3,4 In view of the mechanisms men-
tioned above, we conducted a prospective study to evaluate
the impact of bilateral TT on the clinical activity of GO.
Evaluation of data on the treatment of Graves’ disease
reveals comparable efficacy of antithyroid drugs, radioio-
dine and various forms of surgery for inducing initial
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remission.6 Antithyroid drugs and particularly the extended
forms of surgery alleviate GO and achieve immediate regres-
sion when compared to radioiodine therapy.7 However,
long-term remission is almost unexpected with antithy-
roid drugs and 25–50% relapse rates have been reported
after the cessation of this therapy.8,9 Recurrence rates
lower than with medical and radioiodine therapy have
been reported with lesser forms of surgery. Among 340
patients who were prospectively randomized to bilateral
subtotal thyroidectomy (BST) versus unilateral total and
contralateral subtotal thyroidectomy (UTCST), recurrent
hyperthyroidism was observed in 9% and 1.7% of the cases,
respectively. The percentage of patients with GO was not
definite and the thyroid remnant left after BST was twice
that of the patients who underwent UTCST in that study.10
Similarly, a retrospective evaluation of 119 and 98 consec-
utive patients treated with BST and TT, respectively, for
Graves’ disease revealed comparable safety despite a sig-
nificant relapse rate of 5.9% in the BST arm.11 Concerning
the patients with GO, lesser forms of surgery that were
terminated with a small remnant left behind unavoidably
resulted in aggravation of eye disease in 16–40% of the
patients and necessitated the use of steroid therapy in
some of those cases.12,13 In contrast, radioiodine or subtotal
thyroidectomy resistant relapses of Graves’ disease with
progressive ophthalmopathy were satisfactorily treated by
TT and resulted in the normalization of TRAb levels and
improvement of eye signs in 86% and 96%, respectively, of
patients.8 In another series, worsening of GO and persis-
tent hyperthyroidism was observed in 8% of the patients
in the subtotal thyroidectomy group and in none of the
patients in the TT group, suggesting a favourable outcome
after TT.14
The hyperthyroidic state of Graves’ disease sometimes
resembles the toxic phase of Hashimoto’s thyroiditis.
However, the disorder of Hashitoxicosis has been excluded
in our study by the examination of pathological specimens
to reliably confirm the features of Graves’ disease in all
patients. The incidence of thyroid cancer, most frequently
the papillary type, varies from 5% to 10% in patients with
Graves’ disease, especially in those with a solid nodule in
the parenchyma.15 The incidence of malignancy was nil 
in our study. This might be partially due to the inclusion
criteria of this study, where the absence of nodularity in
the ultrasound examination was a prerequisite.
Our patient cohort was quite homogeneous in terms
of preoperative medical management and the applied sur-
gery, and TT resulted in a significant reduction in TRAb
levels with concomitant regression of recurrent GO in all
patients. The operative morbidity was 3% and mortality
was nil. The long-term consequences of permanent hypo-
thyroidism, which is the ultimate result of TT, are of major
concern.
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